Does China’s centralized volume-based drug procurement policy facilitate the transition from imitation to innovation for listed pharmaceutical companies? Empirical tests based on double difference model

Introduction: The normalized implementation of the centralized volume-based procurement policy for pharmaceuticals is a concerted push for supply-side structural reform of the pharmaceutical industry in China. The impact of the centralized drug procurement policy on pharmaceutical companies' tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Yang, Zhuang, Qian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266233/
https://www.ncbi.nlm.nih.gov/pubmed/37324496
http://dx.doi.org/10.3389/fphar.2023.1192423

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266233/
https://www.ncbi.nlm.nih.gov/pubmed/37324496
http://dx.doi.org/10.3389/fphar.2023.1192423

Ejemplares similares